GSK GSK.L
GSK is a global pharmaceutical company that develops and commercializes medicines and vaccines, with a business model based on innovation and intellectual property. GSK trades at a P/E of 15.65 with an operating margin of 30.94% and an ROIC of 28.59%, reflecting a quality business, although earnings growth is negative (-69.5%) and free cash flow conversion is weak (32.19).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
GSK is a global pharmaceutical company that develops and commercializes medicines and vaccines, with a business model based on innovation and intellectual property. GSK trades at a P/E of 15.65 with an operating margin of 30.94% and an ROIC of 28.59%, reflecting a quality business, although earnings growth is negative (-69.5%) and free cash flow conversion is weak (32.19).
Score by category
| Category | Score |
|---|---|
| Financial health | 6.8 |
| Quality / Moat | 8.1 |
| Valuation | 6.2 |
| Growth | 2.9 |
| Dividend | 4.6 |
| Momentum | 4.9 |
| Risk & Context | 8.9 |
OVERALL SCORE: 6.5/10
Context and risks
GSK has no direct exposure to commodities or interest rates in a material way. The main risk is regulatory, with pressure on drug prices in the US and Europe, and dependence on new drug approvals.
News considered in the analysis
- Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum — El respaldo de un bróker y la ampliación del pipeline oncológico refuerzan la tesis de crecimiento, aunque el impacto financiero del acuerdo es limitado frente a la capitalización de GSK.
- GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger? — La expansión en oncología mediante acuerdos de licencia es positiva para el crecimiento a largo plazo, pero el desembolso inicial es modesto y el éxito clínico aún no está garantizado.
- GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity — La alianza con HUTCHMED amplía el acceso a activos oncológicos prometedores, pero añade riesgo de ejecución y depende de aprobaciones regulatorias futuras.
- GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care — Titular estratégico sin datos financieros concretos; no aporta información nueva cuantificable para la valoración.
- GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape — El objetivo de ventas a medio plazo y el plan de ahorro son positivos, pero la probabilidad de alcanzarlos es incierta y el mercado ya lo descuenta parcialmente.
Verdict: Hold positions: the quality of the business and the oncology pipeline offset the weak current growth, but the valuation offers no margin of safety.
Main risk: The main risk is regulatory pressure on drug prices in the US and Europe, which could compress margins and limit revenue growth.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →